RETRACTED ARTICLE: Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial
Hany M Dabbous, Manal H El-Sayed, Gihan El Assal, Hesham Elghazaly, Fatma F S Ebeid, Ahmed F Sherief, Maha Elgaafary, Ehab Fawzy, Sahar M Hassany, Ahmed R Riad, Mohamed A Tageldin
Scientific Reports, doi:10.1038/s41598-021-85227-0
Favipiravir is considered a potential treatment for COVID-19 due its efficacy against different viral infections. We aimed to explore the safety and efficacy of favipiravir in treatment of COVID-19 mild and moderate cases. It was randomized-controlled open-label interventional phase 3 clinical trial [NCT04349241]. 100 patients were recruited from 18th April till 18th May. 50 patients received favipiravir 3200 mg at day 1 followed by 600 mg twice (day 2-day 10). 50 patients received hydroxychloroquine 800 mg at day 1 followed by 200 mg twice (day 2-10) and oral oseltamivir 75 mg/12 h/day for 10 days. Patients were enrolled from Ain Shams University Hospital and Assiut University Hospital. Both arms were comparable as regards demographic characteristics and comorbidities. The average onset of SARS-CoV-2 PCR negativity was 8.1 and 8.3 days in HCQ-arm and favipiravir-arm respectively. 55.1% of those on HCQ-arm turned PCR negative at/or before 7th day from diagnosis compared to 48% in favipiravir-arm (p = 0.7). 4 patients in FVP arm developed transient transaminitis on the other hand heartburn and nausea were reported in about 20 patients in HCQarm. Only one patient in HCQ-arm died after developing acute myocarditis resulted in acute heart failure. Favipiravir is a safe effective alternative for hydroxychloroquine in mild or moderate COVID-19 infected patients. At the end of 2019, the entire world saw the first appearance of the coronavirus disease 2019 (COVID-19) 1 . By March 2020, it was declared a pandemic by the World Health Organization (WHO). Globally, more than 83 million cases of COVID-19 and more than 1.5 million deaths have been reported so far 2, 3 . The first case registered in Egypt was in February 2020, and, since then, the number has been increasing. By early July 2020, nearly 1.5 hundred thousand confirmed cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and about 8000 deaths were reported by the Ministry of Health (MoH) 4 . In Egypt, the curve of new cases prompted an investigation into the different treatment options to find the most effective and safe choice for COVID-19 patients. Favipiravir (FPV) is one of the potential options according to a Chinese study, considering its past history of efficacy against viral influenza 5 . Being a novel RNA-dependent RNA polymerase (RdRp) inhibitor, FPV has also shown efficacy against the Ebola virus 6, 7 . FVP, known as Avigan, is a pyrazine derivative and guanine analogue that acts as a chain termination tool and prevents RNA elongation. Favipiravir demonstrated anti-viral activities against a broad array of RNA viruses, including arenaviruses, bunyaviruses, and filoviruses 8 . In Japan, favipiravir has been approved for influenza A resistant to neuraminidase inhibitors 9 . Also, an expert consensus group in China suggested that chloroquine improved lung imaging and shortened the disease course 10 . However, a number of additional reports have since shown no positive..
Author contributions H.D. shared in the protocol of the study, data collection and writing the manuscript. A.F.S. data collection and writing the manuscript. All other authors contributed equally in Management and follow up of patients beside data collection. By M.E. statistical analysis was done. Study design and revision of the manuscript by M.E.-S. and F.E. were done.
R E T R A C T E D A R T I C L E
Competing interests The authors declare no competing interests.
References
Borba, Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: Preliminary safety results of a randomized, doubleblinded, phase IIb clinical trial (CloroCovid-19 Study), JAMA Netw. Open,
doi:10.1001/jamanetworkopen.2020.8857Cai, Experimental treatment with favipiravir for COVID-19: An open-label control study, Engineering
Chan, A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster, Lancet
De Barros, COVID-19 pandemic-A narrative review of the potential roles of chloroquine and hydroxychloroquine, Pain Physician
Furuta, Komeno, Nakamura, Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase, Proc. Jpn. Acad. Ser. B Phys. Biol. Sci
Gao, Tian, Yang, Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies, Biosci. Trends
Geleris, Sun, Platt, Zucker, Observational study of hydroxychloroquine in hospitalized patients with COVID-19, N. Engl. J. Med
Hayden, Shindo, Influenza virus polymerase inhibitors in clinical development, Curr. Opin. Infect. Dis
Huang, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet
Jun, A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19), J. Zhejiang Univ
Liu, Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro, Cell Discov
Madelain, Ebola virus dynamics in mice treated with favipiravir, Antiviral Res
Mahevas, No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: Results of a study using routinely collected data to emulate a target trial, BMJ
Pilkington, Pepperrell, Hill, A review of the safety of favipiravir-A potential treatment in the COVID-19 pandemic?, J. Virus Erad
Saber-Ayad, Saleh, Abu-Gharbieh, The rationale for potential pharmacotherapy of COVID-19, Pharmaceuticals
Tang, Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: Open label, randomised controlled trial, BMJ
Wang, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res
Zhonghua, He, Hu, Za, Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia
Zhou, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study [published correction appears in, Lancet
Zhou, Dai, Tong, COVID-19: A recommendation to examine the effect of hydroxychloroquine in preventing infection and progression, J. Antimicrob. Chemother
{ 'indexed': {'date-parts': [[2024, 5, 11]], 'date-time': '2024-05-11T00:26:51Z', 'timestamp': 1715387211870},
'reference-count': 30,
'publisher': 'Springer Science and Business Media LLC',
'issue': '1',
'license': [ { 'start': { 'date-parts': [[2021, 3, 31]],
'date-time': '2021-03-31T00:00:00Z',
'timestamp': 1617148800000},
'content-version': 'tdm',
'delay-in-days': 0,
'URL': 'https://creativecommons.org/licenses/by/4.0'},
{ 'start': { 'date-parts': [[2021, 3, 31]],
'date-time': '2021-03-31T00:00:00Z',
'timestamp': 1617148800000},
'content-version': 'vor',
'delay-in-days': 0,
'URL': 'https://creativecommons.org/licenses/by/4.0'}],
'content-domain': {'domain': ['link.springer.com'], 'crossmark-restriction': False},
'abstract': '<jats:title>Abstract</jats:title><jats:p><jats:italic>Favipiravir</jats:italic> is considered '
'a potential treatment for COVID-19 due its efficacy against different viral infections. We '
'aimed to explore the safety and efficacy of <jats:italic>favipiravir</jats:italic> in '
'treatment of COVID-19 mild and moderate cases. It was randomized-controlled open-label '
'interventional phase 3 clinical trial [NCT04349241]. 100 patients were recruited from 18th '
'April till 18th May. 50 patients received favipiravir 3200\xa0mg at day 1 followed by 600\xa0'
'mg twice (day 2–day 10). 50 patients received hydroxychloroquine 800\xa0mg at day 1 followed '
'by 200\xa0mg twice (day 2–10) and oral oseltamivir 75\xa0mg/12\xa0h/day for 10\xa0days. '
'Patients were enrolled from Ain Shams University Hospital and Assiut University Hospital. '
'Both arms were comparable as regards demographic characteristics and comorbidities. The '
'average onset of SARS-CoV-2 PCR negativity was 8.1 and 8.3\xa0days in HCQ-arm and '
'favipiravir-arm respectively. 55.1% of those on HCQ-arm turned PCR negative at/or before 7th '
'day from diagnosis compared to 48% in favipiravir-arm (p\u2009=\u20090.7). 4 patients in FVP '
'arm developed transient transaminitis on the other hand heartburn and nausea were reported in '
'about 20 patients in HCQ-arm. Only one patient in HCQ-arm died after developing acute '
'myocarditis resulted in acute heart failure. Favipiravir is a safe effective alternative for '
'hydroxychloroquine in mild or moderate COVID-19 infected patients.</jats:p>',
'DOI': '10.1038/s41598-021-85227-0',
'type': 'journal-article',
'created': {'date-parts': [[2021, 3, 31]], 'date-time': '2021-03-31T10:03:51Z', 'timestamp': 1617185031000},
'update-policy': 'http://dx.doi.org/10.1007/springer_crossmark_policy',
'source': 'Crossref',
'is-referenced-by-count': 24,
'title': 'RETRACTED ARTICLE: Safety and efficacy of favipiravir versus hydroxychloroquine in management of '
'COVID-19: A randomised controlled trial',
'prefix': '10.1038',
'volume': '11',
'author': [ {'given': 'Hany M.', 'family': 'Dabbous', 'sequence': 'first', 'affiliation': []},
{'given': 'Manal H.', 'family': 'El-Sayed', 'sequence': 'additional', 'affiliation': []},
{'given': 'Gihan', 'family': 'El Assal', 'sequence': 'additional', 'affiliation': []},
{'given': 'Hesham', 'family': 'Elghazaly', 'sequence': 'additional', 'affiliation': []},
{'given': 'Fatma F. S.', 'family': 'Ebeid', 'sequence': 'additional', 'affiliation': []},
{'given': 'Ahmed F.', 'family': 'Sherief', 'sequence': 'additional', 'affiliation': []},
{'given': 'Maha', 'family': 'Elgaafary', 'sequence': 'additional', 'affiliation': []},
{'given': 'Ehab', 'family': 'Fawzy', 'sequence': 'additional', 'affiliation': []},
{'given': 'Sahar M.', 'family': 'Hassany', 'sequence': 'additional', 'affiliation': []},
{'given': 'Ahmed R.', 'family': 'Riad', 'sequence': 'additional', 'affiliation': []},
{'given': 'Mohamed A.', 'family': 'TagelDin', 'sequence': 'additional', 'affiliation': []}],
'member': '297',
'published-online': {'date-parts': [[2021, 3, 31]]},
'reference': [ { 'key': '85227_CR1',
'doi-asserted-by': 'publisher',
'first-page': '497e506',
'DOI': '10.1016/S0140-6736(20)30183-5',
'volume': '395',
'author': 'C Huang',
'year': '2020',
'unstructured': 'Huang, C. et al. Clinical features of patients infected with 2019 novel '
'coronavirus in Wuhan, China. Lancet 395, 497e506 (2020).',
'journal-title': 'Lancet'},
{ 'key': '85227_CR2',
'unstructured': 'World Health Organization. '
'.https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports. '
'Accessed on 3/1/2021.'},
{ 'key': '85227_CR3',
'first-page': '514e23',
'volume': '395',
'author': 'JF Chan',
'year': '2020',
'unstructured': 'Chan, J. F. et al. A familial cluster of pneumonia associated with the '
'2019 novel coronavirus indicating person-to-person transmission: a study '
'of a family cluster. Lancet 395, 514e23 (2020).',
'journal-title': 'Lancet'},
{ 'key': '85227_CR4',
'unstructured': 'Egyptian Ministry of Health. '
'https://www.care.gov.eg/EgyptCare/Index.aspx. Accessed 3/1/2021.'},
{ 'key': '85227_CR5',
'doi-asserted-by': 'publisher',
'first-page': '1192',
'DOI': '10.1016/j.eng.2020.03.007',
'volume': '6',
'author': 'Q Cai',
'year': '2020',
'unstructured': 'Cai, Q. et al. Experimental treatment with favipiravir for COVID-19: An '
'open-label control study. Engineering 6, 1192–1198 (2020).',
'journal-title': 'Engineering'},
{ 'key': '85227_CR6',
'doi-asserted-by': 'publisher',
'first-page': '70',
'DOI': '10.1016/j.antiviral.2015.08.015',
'volume': '123',
'author': 'V Madelain',
'year': '2015',
'unstructured': 'Madelain, V. et al. Ebola virus dynamics in mice treated with '
'favipiravir. Antiviral Res. 123, 70–77 (2015).',
'journal-title': 'Antiviral Res.'},
{ 'issue': '7',
'key': '85227_CR7',
'doi-asserted-by': 'publisher',
'first-page': '449',
'DOI': '10.2183/pjab.93.027',
'volume': '93',
'author': 'Y Furuta',
'year': '2017',
'unstructured': 'Furuta, Y., Komeno, T. & Nakamura, T. Favipiravir (T-705), a broad '
'spectrum inhibitor of viral RNA polymerase. Proc. Jpn. Acad. Ser. B '
'Phys. Biol. Sci. 93(7), 449–463 (2017).',
'journal-title': 'Proc. Jpn. Acad. Ser. B Phys. Biol. Sci.'},
{ 'issue': '2',
'key': '85227_CR8',
'doi-asserted-by': 'publisher',
'first-page': '176',
'DOI': '10.1097/QCO.0000000000000532',
'volume': '32',
'author': 'FG Hayden',
'year': '2019',
'unstructured': 'Hayden, F. G. & Shindo, N. Influenza virus polymerase inhibitors in '
'clinical development. Curr. Opin. Infect. Dis. 32(2), 176–186 (2019).',
'journal-title': 'Curr. Opin. Infect. Dis.'},
{ 'key': '85227_CR9',
'unstructured': 'Zhonghua, J., He, H., Hu, X. & Za, Z. Expert consensus on chloroquine '
'phosphate for the treatment of novel coronavirus pneumonia. 43, E019 '
'(2020).'},
{ 'issue': '369',
'key': '85227_CR10',
'doi-asserted-by': 'publisher',
'first-page': 'm1849',
'DOI': '10.1136/bmj.m1849',
'volume': '14',
'author': 'W Tang',
'year': '2020',
'unstructured': 'Tang, W. et al. Hydroxychloroquine in patients with mainly mild to '
'moderate coronavirus disease 2019: Open label, randomised controlled '
'trial. BMJ 14(369), m1849 (2020).',
'journal-title': 'BMJ'},
{ 'key': '85227_CR11',
'unstructured': 'Zhou, D., Dai, S. M. & Tong, Q. COVID-19: A recommendation to examine '
'the effect of hydroxychloroquine in preventing infection and '
'progression. J. Antimicrob. Chemother., dkaa114.'},
{ 'key': '85227_CR12',
'doi-asserted-by': 'publisher',
'first-page': 'Article 16',
'DOI': '10.1038/s41421-020-0156-0',
'volume': '6',
'author': 'J Liu',
'year': '2020',
'unstructured': 'Liu, J. et al. Hydroxychloroquine, a less toxic derivative of '
'chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. '
'Cell Discov. 6, Article 16 (2020).',
'journal-title': 'Cell Discov.'},
{ 'issue': '1',
'key': '85227_CR13',
'doi-asserted-by': 'publisher',
'first-page': '72',
'DOI': '10.5582/bst.2020.01047',
'volume': '14',
'author': 'J Gao',
'year': '2020',
'unstructured': 'Gao, J., Tian, Z. & Yang, X. Breakthrough: Chloroquine phosphate has '
'shown apparent efficacy in treatment of COVID-19 associated pneumonia in '
'clinical studies. Biosci. Trends 14(1), 72–73 (2020).',
'journal-title': 'Biosci. Trends'},
{ 'key': '85227_CR14',
'unstructured': 'Information for Clinicians on Investigational Therapeutics for Patients '
'with COVID-19. '
'https://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html.'},
{ 'key': '85227_CR15',
'unstructured': 'Food and Drug Administration. www.fda.gov/media/138945/download.'},
{ 'key': '85227_CR16',
'unstructured': 'American College of Cardiology. Ventricular arrhythmia risk due to '
'hydroxychloroquine-azithromycin treatment for COVID-19. '
'https://www.acc.org/latest-in-cardiology/articles/2020/03/27/14/00/.'},
{ 'issue': '3',
'key': '85227_CR17',
'doi-asserted-by': 'publisher',
'first-page': '269',
'DOI': '10.1038/s41422-020-0282-0',
'volume': '30',
'author': 'M Wang',
'year': '2020',
'unstructured': 'Wang, M. et al. Remdesivir and chloroquine effectively inhibit the '
'recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. '
'30(3), 269–271 (2020).',
'journal-title': 'Cell Res.'},
{ 'key': '85227_CR18',
'doi-asserted-by': 'publisher',
'DOI': '10.1101/2020.03.17.20037432v4',
'author': 'C Chen',
'year': '2020',
'unstructured': 'Chen, C., Zhang, Y., Huang, J. & Yin, P. Favipiravir versus arbidol for '
'COVID-19: A randomized clinical trial. medRxiv '
'https://doi.org/10.1101/2020.03.17.20037432v4 (2020).',
'journal-title': 'medRxiv'},
{ 'key': '85227_CR19',
'doi-asserted-by': 'publisher',
'first-page': '45',
'DOI': '10.1016/S2055-6640(20)30016-9',
'volume': '6',
'author': 'V Pilkington',
'year': '2020',
'unstructured': 'Pilkington, V., Pepperrell, T. & Hill, A. A review of the safety of '
'favipiravir—A potential treatment in the COVID-19 pandemic?. J. Virus '
'Erad. 6, 45–51 (2020).',
'journal-title': 'J. Virus Erad.'},
{ 'issue': '4S',
'key': '85227_CR20',
'first-page': 'S351',
'volume': '23',
'author': 'CM de Barros',
'year': '2020',
'unstructured': 'de Barros, C. M. et al. COVID-19 pandemic—A narrative review of the '
'potential roles of chloroquine and hydroxychloroquine. Pain Physician '
'23(4S), S351–S366 (2020).',
'journal-title': 'Pain Physician'},
{ 'issue': '10229',
'key': '85227_CR21',
'doi-asserted-by': 'publisher',
'first-page': '1054',
'DOI': '10.1016/S0140-6736(20)30566-3',
'volume': '395',
'author': 'F Zhou',
'year': '2020',
'unstructured': 'Zhou, F. et al. Clinical course and risk factors for mortality of adult '
'inpatients with COVID-19 in Wuhan, China: A retrospective cohort study '
'[published correction appears in Lancet. 2020 Mar 28;395(10229):1038]. '
'Lancet 395(10229), 1054–1062 (2020).',
'journal-title': 'Lancet'},
{ 'key': '85227_CR22',
'first-page': '215',
'volume': '49',
'author': 'C Jun',
'year': '2020',
'unstructured': 'Jun, C. et al. A pilot study of hydroxychloroquine in treatment of '
'patients with common coronavirus disease-19 (COVID-19). J. Zhejiang '
'Univ. 49, 215–219 (2020).',
'journal-title': 'J. Zhejiang Univ.'},
{ 'key': '85227_CR23',
'doi-asserted-by': 'publisher',
'DOI': '10.1101/2020.03.22.20040758v3',
'author': 'Z Chen',
'year': '2020',
'unstructured': 'Chen, Z. et al. Efficacy of hydroxychloroquine in patients with '
'COVID-19: Results of a randomized clinical trial. medRxiv '
'https://doi.org/10.1101/2020.03.22.20040758v3 (2020).',
'journal-title': 'medRxiv'},
{ 'key': '85227_CR24',
'doi-asserted-by': 'publisher',
'first-page': 'm1844',
'DOI': '10.1136/bmj.m1844',
'volume': '369',
'author': 'M Mahevas',
'year': '2020',
'unstructured': 'Mahevas, M. et al. No evidence of clinical efficacy of '
'hydroxychloroquine in patients hospitalized for COVID-19 infection with '
'oxygen requirement: Results of a study using routinely collected data to '
'emulate a target trial. BMJ 369, m1844 (2020).',
'journal-title': 'BMJ'},
{ 'key': '85227_CR25',
'doi-asserted-by': 'publisher',
'DOI': '10.1101/2020.04.10.20060558v2',
'author': 'W Tang',
'year': '2020',
'unstructured': 'Tang, W. et al. Hydroxychloroquine in patients mainly with mild to '
'moderate COVID-19: An open-label, randomized, controlled trial. medRxiv '
'https://doi.org/10.1101/2020.04.10.20060558v2 (2020).',
'journal-title': 'medRxiv'},
{ 'key': '85227_CR26',
'doi-asserted-by': 'publisher',
'DOI': '10.1101/2020.04.16.20065920v1.full.pdf',
'author': 'J Magagnoli',
'year': '2020',
'unstructured': 'Magagnoli, J. et al. Outcomes of hydroxychloroquine usage in United '
'States veterans hospitalized with COVID-19. medRxiv '
'https://doi.org/10.1101/2020.04.16.20065920v1.full.pdf (2020).',
'journal-title': 'medRxiv'},
{ 'issue': '4',
'key': '85227_CR27',
'doi-asserted-by': 'publisher',
'first-page': 'e208857',
'DOI': '10.1001/jamanetworkopen.2020.8857',
'volume': '3',
'author': 'M Borba',
'year': '2020',
'unstructured': 'Borba, M. et al. Chloroquine diphosphate in two different dosages as '
'adjunctive therapy of hospitalized patients with severe respiratory '
'syndrome in the context of coronavirus (SARS-CoV-2) infection: '
'Preliminary safety results of a randomized, double-blinded, phase IIb '
'clinical trial (CloroCovid-19 Study). JAMA Netw. Open 3(4), e208857. '
'https://doi.org/10.1001/jamanetworkopen.2020.8857 (2020).',
'journal-title': 'JAMA Netw. Open'},
{ 'key': '85227_CR28',
'doi-asserted-by': 'publisher',
'first-page': '2411',
'DOI': '10.1056/NEJMoa2012410',
'volume': '382',
'author': 'J Geleris',
'year': '2020',
'unstructured': 'Geleris, J., Sun, Y., Platt, J. & Zucker, J. Observational study of '
'hydroxychloroquine in hospitalized patients with COVID-19. N. Engl. J. '
'Med. 382, 2411–2418 (2020).',
'journal-title': 'N. Engl. J. Med.'},
{ 'issue': '5',
'key': '85227_CR29',
'doi-asserted-by': 'publisher',
'first-page': '96',
'DOI': '10.3390/ph13050096',
'volume': '13',
'author': 'M Saber-Ayad',
'year': '2020',
'unstructured': 'Saber-Ayad, M., Saleh, M. A. & Abu-Gharbieh, E. The rationale for '
'potential pharmacotherapy of COVID-19. Pharmaceuticals 13(5), 96 (2020).',
'journal-title': 'Pharmaceuticals'},
{ 'issue': '1',
'key': '85227_CR30',
'doi-asserted-by': 'publisher',
'first-page': '904',
'DOI': '10.1186/s13063-020-04825-x.PMID:33129363;PMCID:PMC7602769',
'volume': '21',
'author': 'M Bosaeed',
'year': '2020',
'unstructured': 'Bosaeed, M. et al. A trial of favipiravir and hydroxychloroquine '
'combination in adults hospitalized with moderate and severe Covid-19: A '
'structured summary of a study protocol for a randomised controlled '
'trial. Trials 21(1), 904. '
'https://doi.org/10.1186/s13063-020-04825-x.PMID:33129363;PMCID:PMC7602769 '
'(2020).',
'journal-title': 'Trials'}],
'container-title': 'Scientific Reports',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://www.nature.com/articles/s41598-021-85227-0.pdf',
'content-type': 'application/pdf',
'content-version': 'vor',
'intended-application': 'text-mining'},
{ 'URL': 'https://www.nature.com/articles/s41598-021-85227-0',
'content-type': 'text/html',
'content-version': 'vor',
'intended-application': 'text-mining'},
{ 'URL': 'https://www.nature.com/articles/s41598-021-85227-0.pdf',
'content-type': 'application/pdf',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2022, 12, 3]],
'date-time': '2022-12-03T06:12:31Z',
'timestamp': 1670047951000},
'score': 1,
'resource': {'primary': {'URL': 'https://www.nature.com/articles/s41598-021-85227-0'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2021, 3, 31]]},
'references-count': 30,
'journal-issue': {'issue': '1', 'published-online': {'date-parts': [[2021, 12]]}},
'alternative-id': ['85227'],
'URL': 'http://dx.doi.org/10.1038/s41598-021-85227-0',
'relation': { 'has-preprint': [ { 'id-type': 'doi',
'id': '10.21203/rs.3.rs-83677/v2',
'asserted-by': 'object'},
{ 'id-type': 'doi',
'id': '10.21203/rs.3.rs-83677/v1',
'asserted-by': 'object'}]},
'ISSN': ['2045-2322'],
'subject': [],
'container-title-short': 'Sci Rep',
'published': {'date-parts': [[2021, 3, 31]]},
'assertion': [ { 'value': '22 September 2020',
'order': 1,
'name': 'received',
'label': 'Received',
'group': {'name': 'ArticleHistory', 'label': 'Article History'}},
{ 'value': '25 February 2021',
'order': 2,
'name': 'accepted',
'label': 'Accepted',
'group': {'name': 'ArticleHistory', 'label': 'Article History'}},
{ 'value': '31 March 2021',
'order': 3,
'name': 'first_online',
'label': 'First Online',
'group': {'name': 'ArticleHistory', 'label': 'Article History'}},
{ 'value': '18 September 2021',
'order': 4,
'name': 'change_date',
'label': 'Change Date',
'group': {'name': 'ArticleHistory', 'label': 'Article History'}},
{ 'value': 'Correction',
'order': 5,
'name': 'change_type',
'label': 'Change Type',
'group': {'name': 'ArticleHistory', 'label': 'Article History'}},
{ 'value': 'This article has been retracted. Please see the Retraction Notice for more '
'detail:',
'order': 6,
'name': 'change_details',
'label': 'Change Details',
'group': {'name': 'ArticleHistory', 'label': 'Article History'}},
{ 'value': 'https://doi.org/10.1038/s41598-021-98683-5',
'URL': 'https://doi.org/10.1038/s41598-021-98683-5',
'order': 7,
'name': 'change_details',
'label': 'Change Details',
'group': {'name': 'ArticleHistory', 'label': 'Article History'}},
{ 'value': 'The authors declare no competing interests.',
'order': 1,
'name': 'Ethics',
'group': {'name': 'EthicsHeading', 'label': 'Competing interests'}}],
'article-number': '7282'}
